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 Objectives: Real-time monitoring of disease status would be beneficial for timely 
decision making in the treatment of urothelial cancer (UC), and may accelerate the evaluation 
of clinical trials. Use of cell free tumour DNA (cftDNA) as a biomarker in liquid biopsy is 
minimally invasive and its successful use has been reported in various cancer types, including 
UC. The objective of this study was to evaluate the use of digital droplet PCR (ddPCR)-based 
assays to monitor UC after treatment.  
 Method and Materials: Blood, urine and matching formalin fixed, paraffin 
embedded (FFPE) diagnostic specimens were collected from 20 patients diagnosed with stage 
T1 (n=2) and T2/T3 (n=18) disease. SNaPshot assays, Sanger sequencing and whole exome 
sequencing (WES) were used to identify tumour-specific mutations, and somatic mutation 
status was confirmed using patient-matched DNAs extracted from buffy coats and peripheral 
blood mononucleocytes. The ddPCR assays of the tumour-specific mutations were used to 
detect the fractional abundance of cftDNA in plasma and urine. 
 Results: SNaPshot and Sanger sequencing identified point mutations in 70% of the 
patients that were assayable by ddPCR. Cases of remission and relapse monitored by assays 
for PIK3CA E542K and TP53 Y163C mutations in plasma and urine concurred with clinical 
observations up to 48 months from the start of chemotherapy. A new ddPCR assay for the 
telomerase reverse transcriptase (TERT) promoter (-124) mutation was developed. The TERT 
assay was able to detect mutations in cases below the limit of detection by SNaPshot. WES 
identified a novel mutation, CNTNAP4 G727*. A ddPCR assay designed to detect this 
mutation was able to distinguish mutant from wild-type alleles.  
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 Conclusions: The study demonstrated that ddPCR assays could be used to detect 
cftDNA in liquid biopsy monitoring of the post-therapy disease status in patients with UC. 
Overall, 70% of the patients in our study harboured mutations that were assayable by ddPCR. 
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Urothelial carcinoma (UC) is the 10th most common cancer, with 550,000 new cancer 
cases worldwide in 2018 [1]. Risk of progression from non-muscle-invasive bladder cancer 
(NMIBC) to MIBC is high in T1 disease, up to 17% at one year, increasing to 45% at 5 years 
[2]. High-risk NMIBC and MIBC are treated aggressively, often by cystectomy with peri-
operative chemotherapy in the case of MIBC. Effectiveness of treatments of metastatic 
disease is limited [3, 4]. The recent technological advance in identifying cell free tumour 
DNA (cftDNA) offers the opportunity to enable real-time diagnosis in combination with new 
and existing diagnostic modalities, which may facilitate the selection of therapy options and 
more accurate prediction of disease prognosis [5].    
 DNA is released into the bloodstream or urine as cell-free DNA (cfDNA), and DNA 
released from tumours, cftDNA, can be differentiated from normal cfDNA using tumour-
specific mutations as markers [6]. Use of cftDNA-based markers in liquid biopsy samples 
may enable a minimally invasive approach to disease monitoring, and facilitates longitudinal, 
repeated sampling. cftDNA is detectable in many cancer types, including UC [7], albeit the 
levels may vary [8]. Studies showed that real-time monitoring of tumour burden is possible, 
when measured as variant allele frequency or fractional abundance (FA) of cftDNA, and it 
can represent DNA from both primary and metastatic tumours [6, 9, 10].  
 Detection of the UC hotspot mutations FGFR3 S249C and Y373C, and PIK3CA 
E545K in plasma and urine cfDNA was used in disease surveillance, and the level of cftDNA 
was associated with later disease progression in NMIBC and recurrence in patients that were 
undergoing cystectomy [11]. A custom-designed panel of one to six patient-specific ddPCR 
assays, developed based on the pre-screening of the tumour-specific mutations by next-
generation sequencing, was successfully utilised in longitudinal monitoring of NMIBC [12]. 
An extension of this strategy that used 84 personalized ddPCR assays targeting 61 genes in 
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cftDNA detected a relapse in MIBC patients with a lead-time of 101 days after cystectomy 
over radiographic imaging [13]. The level of cftDNA in liquid biopsy could be detected by a 
panel of general or UC-specific mutations and structural alterations, such as copy number 
alterations (CNAs) [13-18].  
 The underlying principle of ddPCR is a single PCR reaction split into 10,000 to 
20,000 discreet measurements in "droplets", which enables quantification of a single mutant 
DNA sequence amongst thousands of wild-type sequences [6]. While relatively limited in the 
flexibility of mutational coverage in monitoring patients, it does have an advantage in 
simplicity and sensitivity. In this study, we have tested the feasibility and practicality in 
performing commercially available ddPCR-based assays and in designing new ddPCR assays 
where pre-existing assays were not available.  
 
2. Materials and Methods 
 
2.1. Patients and DNA samples 
 Samples were collected under the approvals by The West of Scotland Research Ethics 
Service (REC 10/S0704/18) and MI84 ECMC Blood Biomarkers Study. The survival status 
of patients is as of 1/1/2018. The matched formalin fixed, paraffin embedded (FFPE) samples 
were acquired from the NHS Greater Glasgow and Clyde Biorepository (16/WS/0207 app 
122). Blood samples were processed at the Queen Elizabeth University Hospital or The 
Analytical Services Unit (ASU), University of Glasgow. Macrodissection of tumour areas, 
identified by the pathologist, was performed from five to ten 8-µm FFPE tissue sections. 
DNAs from plasma, buffy coat, peripheral blood mononucleocytes (PBMCs), and urine were 




2.2. SNaPshot assay and Sanger sequencing 
 Hotspot mutations in the TERT promotor, PIK3CA, FGFR3 and RAS genes were 
assayed by SNaPshot analysis [19] in tumour DNAs. Sanger sequencing was used to identify 
TP53 mutations. The patient-matched buffy coat DNAs were used as control for somatic 
mutations. Further details of SNaPshot assay and Sanger sequencing are provided in 
Supplementary Methods.  
 
2.3. Whole Exome Sequencing (WES) 
 WES and the subsequent bioinformatic analysis was performed by Glasgow Polyomics 
Facility, University of Glasgow. Whole exome capture was carried out using the SeqCap EZ 
Exome+UTR kit (Roche, Pleasanton, CA, USA), sequenced using the NextSeq 500 platform 
(Illumina, San Diego, CA, USA) and 2x 75 bp reads were generated. The sequence data was 
aligned to the GRCh37 (hg19) genome using BWA (Version 0.7.10-r789) and variants were 
called using the Genome Analysis Toolkit (GATK, Broad Institute, Cambridge, USA). 
Tumour-specific mutations were identified by removing germ-line variants identified in 
PBMCs. Variant annotation and effect prediction was completed using SnpEff [20]. 
 
2.4. The ddPCR 
 A typical ddPCR experiment consisted of a control amplification without the addition 
of template DNA, negative (tumour DNA that does not carry the mutation) and positive 
(tumour DNA that carries the mutation) controls, along with the assays performed with plasma 
and urine cfDNA. DNA input of liquid biopsy was 0.5-8 ng per reaction. BioRad C1000 
Touch thermos cycler was used for PCR in droplets generated, which were analysed by the 
QX200 droplet digital PCR system and Quantasoft (BioRad, Watford, UK). FA of the mutant 
allele was calculated as the number of droplets positive with mutant amplicon, divided by total 
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droplets positive with amplicons. The assays were repeated in at least three independent 
experiments. The CNTNAP4 assay was carried out in duplicate or triplicate in a single assay. 




3.1. Patient characteristics 
 A cohort of 20 patients (2 NMIBC and 18 MIBC) was available (Table 1). Eight 
patients had recurrent disease, 5 of whom had a single recurrence, while others had 3 or 
more. Of 11 deceased patients, 8 (73%) had metastasis. Metastasis was identified in 11% (1 
out of 9) of patients who are alive. Cystectomy with neoadjuvant chemotherapy (NAC), 
radiotherapy with or without chemotherapy were the most common treatment types (70% 






















































 All patients (n = 20) 
 Number % 
Sex   
  Male 17 85.0 
  Female 3 15.0 
Age (Years)   
  Range 43-83  
  Median 67  
  Mean 68  
T Stage   
  pT1 2 10.0 
  pT2 18 90.0 
Grade   
  2 1 5.0 
  3 19 95.0 
Recurrence/Outcome   
  Clinical Recurrence 8 40.0 
  No Recurrence 12 60.0 
Current Status   
  Alive 9 45.0 
  Deceased 11 55.0 
Presence of Metastasis   
  No metastasis  11 55.0 
  Metastasis present 9 45.0 
Survival Time, mean (months)   
  No metastasis 53.8  
  Metastasis present 31.5  
Treatments   
  Cystectomy only 2 10.0 
  Cystectomy and Neo. Adj. Chemotherapy 5 25.0 
  Cystectomy and Radiotherapy 1 5.0 
  Radiotherapy only 6 30.0 
  Radiotherapy and Chemotherapy 3 15.0 
  Chemotherapy only 2 10.0 
  Nephroureterectomy 1 5.0 
Presence of mutations identified in each patient   
  Two mutations 3 15.0 
  Single mutation 11 55.0 
  No mutation  6 30.0 
Mutations identified by SNaPshot    
  PIK3CA E542K 1 5.0 
  PIK3CA E545K 2 10.0 
  TERT -124 11 55.0 
  FGFR3 K650/652M 1 5.0 
Mutations identified by Sanger sequencing   
  TP53 Y163C  1 5.0 
  TP53 P278T 1 5.0 
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Table 2. Details of patients and tumour samples  
 
 
*as of 1/1/2018 





Sex Age Tumour 
Stage/ 
Grade 
Recurrence Metastasis Survival* 
(Months) 
Treatment 1 Treatment 2 Mutations identified in tumour by 
SNaPshot/Sanger sequencing  
1 M 57 pT1bG2 1 0 62 (Alive)  NAC Cystectomy  TERT -124, FGFR3 K650/652M 
2 M 62 pT1cG3 1 0 56 (Alive)  Nephroureterectomy   
3 M 77 pT2G3 0 0 60 (Alive)  NAC Cystectomy  TERT -124, PIK3CA E542K 
4 M 67 pT2G3 0 0 49 (Alive) Radiotherapy Chemotherapy TERT -124 
5 M 81 pT2G3 0 0 50 (Alive)  NAC Cystectomy  TERT -124  
6 M 67 pT2G3 0 0 57 (Alive)  Radiotherapy Chemotherapy  
7 F 83 pT2G3 0 0 70 (Alive)  Radiotherapy  TERT -124 
8 M 65 pT2G3 0 0 64 (Alive)  Radiotherapy  TP53 P278T 
9 M 66 pT2G3 0 0 47  Chemotherapy  TP53 Y163C 
10 M 64 pT2G3 1 0 46  Radiotherapy  TERT -124 
11 M 68 pT2G3 3 1 57 (Alive)  Chemotherapy and 
Radiotherapy 
Cystectomy 
Cystectomy TERT -124 
12 M 79 pT2G3 3 0 27 Radiotherapy   
13 M 63 pT2G3 0 1 29 Radiotherapy  PIK3CA E545K 
14 M 69 pT2G3 0 1 18 NAC Cystectomy  TERT -124 
15 M 70 pT2G3 0 1 28 Cystectomy  TERT -124 
16 M 61 pT2G3 0 1 32 Chemotherapy   
17 F 43 pT2G3 1 1 11 NAC Cystectomy  TERT -124, PIK3CA E545K 
18 M 77 pT2G3 1 1 28 Radiotherapy Chemotherapy TERT -124 
19 F 82 pT2aG3 0 1 21 Cystectomy   
20 M 73 pT2aG3 4 1 58 Radiotherapy    
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3.2. SNaPshot and Sanger sequencing identified assayable mutations in 70% of samples 
 PIK3CA E542K, PI3KCA E545K and TERT promoter (-124) mutations were 
identified by SNaPshot assays in 5%, 10% and 55% of patients, respectively (Table 1, Table 
2). TP53 mutations (P278T and Y163C) were identified by Sanger sequencing in 10% of the 
patients. No FGFR3 S249C or RAS gene mutations were detected. Overall, no mutations 
were identified in 30% of the cases. 
 
3.3. ddPCR analysis of a PIK3CA E542K mutation in plasma cftDNA from a case in 
remission 
Patient 3 was a 77-year-old male, diagnosed with non-metastatic muscle invasive 
disease, with a pT2 G3 tumour that carried a PIK3CA E542K mutation as identified by 
SNaPshot (Table 2). The presence of the PIK3CA E542K mutation was evaluated by ddPCR 
using a commercially available, validated assay, with a limit of detection (LOD) of 0.1%. A 
LOD of the mutant allele defines the lowest fraction of mutant DNA that an assay can 
reliably detect. The PIK3CA E542K mutation was confirmed in the patient’s tumour DNA 
with an FA of 35.7 % (Fig. 1C, Supplementary Results). No mutant signals were observed in 
the absence of template DNA, or in the tumour DNA from Patient 14, that was wildtype for 
the PIK3CA E542K mutation by SNaPshot (Fig. 1A, B). The mutant allele was still detected 
in the plasma of Patient 3 (FA of 4.2%) above the LOD of 0.1% at 1 week after the start of 
NAC (Fig. 1D). The patient subsequently had cystectomy at 3.5 months after NAC. The 
mutant allele was not detected at 45 months after cystectomy (48 months after the start of 
NAC) in plasma or urine (Fig. 1E, F). A minimum of 3 independent experiments were 
performed and the results were replicated (Fig. 1G). The patient is currently in remission after 
5 years and believed to be disease free. Therefore, ddPCR-based monitoring of the PIK3CA 




Fig. 1: ddPCR-based detection of a PIK3CA E542K mutation in plasma and urine 
ctDNA from a case of remission. The plots (A-F) indicate the digital PCR droplets positive 
with wild type (green), mutant (blue), both mutant and wild type (red) amplicons, and those 
with no amplicons (black). The number of positive droplets in the plots depends on the total 
DNA input, therefore fractional abundance (FA) is to be used for comparisons among 
samples.The assays were performed along with negative controls in which no template DNA 
was added (A) and tumour DNA known to be negative for this mutation (Patient 14) (B). 
The PIK3CA E542K assays were performed to monitor the disease status of Patient 3, using 
DNAs extracted from tumour (C), plasma collected at 1 week after the start of NAC, before 
cystectomy (D), plasma (E) and urine (F) collected at 45 months after cystectomy (48 
months from the start of NAC). (G) Summary of FA of the mutant allele within total 
droplets positive with amplicons is shown. Error bars are mean with standard deviation 
based on 5 independent experiments for tumour DNA and 3 independent experiments for 




3.4. ddPCR analysis of a TP53 Y163C mutation in plasma and urine cftDNA from a relapsed 
case 
Patient 9 was a 66-year-old male with a pT2 G3 tumour that was identified with a 
TP53 Y163C mutation by Sanger sequencing (Table 2). The TP53 Y163C mutation was 
confirmed in the patient’s tumour DNA by a commercially available, validated ddPCR assay 
(Fig. 2A). No mutant alleles were detected by ddPCR in plasma collected at 3 weeks into 
cisplatin gemcitabine chemotherapy (Fig. 2B). However, mutant alleles were detected in 
plasma and urine collected at 37 months after the initiation of chemotherapy (FA of 0.80 and 
0.43%, respectively) above the LOD of 0.1% (Fig. 2C-E). Clinically, the patient had a very 
good response to chemotherapy but relapsed and has died from UC at 45 months from the 
initiation of chemotherapy. Therefore, the results of the ddPCR assay matches the clinical 




Fig. 2: ddPCR-based detection of a TP53 Y163C mutation in plasma and urine cell-free 
tumour DNA from a case of relapse. The TP53 Y163C ddPCR assays were performed to 
monitor the disease status of Patient 9, using DNAs extracted from tumour (A), plasma 
collected at 3 weeks (B), and plasma (C) and urine (D) collected at 37 months after the 
initiation of chemotherapy. (E) Fractional abundance of the mutant allele. Error bars are the 





3.5. Application of the new TERT -124 ddPCR assay to the monitoring of plasma from cases 
of patients in remission 
The TERT -124 mutation was identified in 55% of our patients (n=11/20) by SNaPshot 
assay (Table 1). In order to take advantage of this common mutation, a ddPCR assay was 
designed with a new set of probes and previously reported PCR amplification primers [21, 22] 
(Supplementary Results, Fig S1, Fig S2). The new assay was able to detect the presence of the 
TERT -124 mutation correctly with the LOD of 0.5% (Fig S1). The LOD of SNaPshot is 
reported to be between 5-10% [19]. Our results showed that the new ddPCR assay could detect 
the mutant allele in cases below the detection limit of SNaPshot (Fig S2).   
A TERT -124 mutation had been identified in the tumour of Patient 3 by SNaPshot 
(Table 2), as well as the PIK3CA E542K mutation (Fig. 1). The new ddPCR assay showed 
mutant droplets in the patient’s tumour DNA (Fig. 3A) with the FA of 74.1% (Fig. 3D). 
TERT -124 mutant alleles were detected in the plasma collected at 1 week from the start of 
NAC (Fig. 3B) with a FA of 36.0% (Fig. 3D). In contrast, the mutant droplets were not 
detected in the plasma at 45 months post-cystectomy (48 months after the start of NAC) (Fig. 
3C, D). These results are in accordance with our observations for the PIK3CA E542K 
mutation in Patient 3 (Fig. 1). 
 Furthermore, a TERT -124 mutation was identified by SNaPshot in the initial pT2 G3 
tumour of Patient 11 (Table 2). The patient was a 68-year-old male who had metastatic disease 
(para-aortic lymph nodes). The patient was treated with palliative chemotherapy, which led to 
a complete response to treatment and went on to a consolidative radiotherapy to his metastatic 
lymph nodes and his bladder tumour. The patient developed non-muscle invasive disease in 
his bladder and had undergone cystectomy at 38 months from the start of chemotherapy. It is 
unclear whether the tumour is a second primary “recurrent” urothelial tumour or regrowth of a 
residual tumour. Patient’s initial tumour DNA was shown to be positive for the mutant alleles 
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by ddPCR (Fig. 3E) with a FA of 42.1% (Fig. 3I). Some mutant droplets were observed in the 
plasma collected at 1 month after the start of chemotherapy prior to cystectomy (Fig. 3F). The 
FA value (11.3%) was above the LOD for the assay (Fig. 3I). The number of mutant signals 
detected by ddPCR increased in the plasma collected at 2 months and 17 months post-
cystectomy (40 months and 57 months from the start of chemotherapy) (Fig. 3G, H), with a 
FA of 20.0% and 23.0%, respectively (Fig. 3I). Clinically, the patient remained in remission at 
16 months from cystectomy (56 months from the chemotherapy). As it is probable that the 





Fig 3: ddPCR-based detection of the TERT -124 mutation in plasma ctDNA from cases 
of remission and relapse. The new TERT -124 ddPCR assays were applied to monitor the 
disease status of Patient 3 (A-D) and Patient 11 (E-I). In Patient 3, the plots show the results 
of the assay performed using DNAs extracted from tumour (A), plasma at 1 week after the 
initiation of NAC, before cystectomy, (B) plasma collected at 48 months from the start of 
NAC (45 months post-cystectomy) (C), and FA of the mutant allele summarised (D). In 
Patient 11, the plots show the assay results of tumour DNA (E), plasma at 1 month after the 
initiation of chemotherapy, before cystectomy (F), 2 months post-cystectomy (40 months 
from the start of chemotherapy) (G), at 17 months post-cystectomy (57 months from the start 
of chemotherapy) (H), and FA of the mutant allele summarized (I). Error bars are the mean 
and standard deviation based on 3 independent experiments. 
17 
 
3.6. The ddPCR assay for CNTNAP4 gene was developed from WES  
 To identify patient-specific tumour mutations in an unbiased fashion, WES was 
performed in DNAs extracted from FFPE tumours (n=3, Patient 4, 5, and 6) (Fig. 4, 
Supplementary Results, Fig S3A). Three adjacent areas within one FFPE block from Patient 5 
were also sampled to assess the variability of mutations. We found that adjacent areas 5-1, 5-2 
and 5-3, contained 19883, 19858 and 21785 tumour-specific mutations, respectively. This was 
close to the reported mutation rate [23]. Among these, 142 mutations were identified as 
common (Fig. 4A). Following a systematic filtering, we selected a Contactin-Associated 
Protein-Like 4 (CNTNAP4) G727* mutation for assay development. We confirmed the 
presence of this mutation in the tumour DNA by Sanger sequencing, as a secondary peak 
showing a C>A mutation (Fig. 4B). A new ddPCR assay designed was able to distinguish 
mutant and normal genomic DNAs with the LOD of 1% FA of mutant allele (Supplementary 
Results, Fig S4). 
 Patient 5 was an 81-year-old male with a pT2 G3 tumour that carried a TERT -124 
mutation (Table 2, Fig S2A) in addition to the CNTNAP4 G727*. Cystectomy followed 3.5 
months after NAC. The presence of the CNTNAP4 G727* mutation was confirmed in the 
patient’s tumour DNA by ddPCR (Fig. 4C) with a FA of 7.31% (Fig. 4G). Mutant droplets 
were observed in plasma collected 2 months into NAC and at 38 months post-cystectomy, 
with the FA of 0.25% and 0.4%, respectively, below the LOD (Fig. 4D, E, G). However in the 
urine collected at 38 months post-cystectomy, the mutant droplets were detected at FA of 
1.2% (Fig 4F). TERT -124 ddPCR assay was positive in tumour (FA 41.6%) but negative (FA 
0%) in plasma at 2 months and urine at 38 months (data not shown). There was no clinical 





Fig. 4: ddPCR-based detection of a CNTNAP4 G727* mutation identified by WES in the 
plasma and urine. (A) Number of tumour-specific mutations identified by WES in three 
adjacent areas (5-1, 5-2, 5-3) of tumours in Patient 5. 142 mutations were found in common 
between 5-1, 5-2 and 5-3. (B) Sanger sequencing confirmed the presence of the CNTNAP4 
G727* mutation in tumour area 5-1 (arrow). The plots show the results of the new CNTNAP4 
G727* ddPCR assay performed on DNAs extracted from tumour (C), plasma collected at 2 
months after the start of NAC before cystectomy (D), and plasma (E) and urine (F) collected 
at 38 months from cystectomy (41 months from the start of NAC). (G) Summary of FA of the 
mutant allele. Error bars are 95% confidence intervals calculated by the Poisson distribution 
based on the number of positive droplets from duplicates in a single experiment. 
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4. Discussion  
 While a good range of ddPCR assays are commercially available for the detection of 
hotspot mutations in PIK3CA and FGFR3, a limited range was available for TP53 mutations, 
likely due to these mutations being distributed across the gene [24, 25]. Some commercial 
ddPCR assays are validated in silico, however, this did not guarantee that the assays would 
work. We were not able to design a functional FGFR3 K650/652M ddPCR assay due to 
persistent false-positive signals.  
 Inhibition of PI3K was shown to suppress bladder tumours particularly effectively in 
the presence of PIK3CA hotspot mutations, as evaluated in human urothelial cell lines and in 
xenograft mouse models [26]. Various inhibitors for PI3K/AKT/mTOR signalling pathways 
are currently in clinical trials for advanced solid tumours, including those of the bladder [27, 
28], and evaluation of PIK3CA mutational status as a biomarker is a rational approach in 
patient selection, at least in the trial set up.   
 TERT is a part of telomerase protein complex that plays a role in extending the 
telomere length [29]. TERT promotor at -124 and -146 are mutated frequently in UC across all 
stages, but not in normal bladder tissues [29-31]. These mutations are predicted to increase the 
level of TERT transcripts, leading to pro-tumour telomerase activity [29]. Several studies have 
investigated the usefulness of TERT promotor mutations as a urinary cell free biomarker, using 
SNaPshot [21, 22], ddPCR [30] and next generation sequencing with urine sediment DNA 
[32]. Telomerase inhibitors are in clinical trials based on the likely involvement of telomerase 
activity in tumour progression [29]. The ddPCR assay in this study produced meaningful 
results with as little as 1 ng of DNA as starting material, in contrast to SNaPshot that required 
5 ng [33]. The LOD provides important guidance to the decision of positivity of the mutant 
allele in samples. The ddPCR-based assays can have a range of LODs depending on the 
ddPCR assay platforms and the nature of samples, such as different amount of DNA input. For 
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example, the LOD for PIK3CA E542K ddPCR assay, the same BioRad assay we used in this 
study, was reported as 0.1% in the study of metastatic biliary cancers using serum as a liquid 
biopsy [34], while for EGFR T790M and L858R mutations, the LOD was 0.5% using 
fragmented DNA of 100-200bp representing plasma cfDNA size in the study of non-small cell 
lung carcinoma [35].  
 CNTNAP4 (CASPR4) is a member of Neurexin-IV/Caspr/Paranodin (NCP) family of 
cell adhesion and recognition molecules and is expressed in neuronal subpopulations in 
specific brain regions [36]. A function as a tumour suppressor was shown in the other family 
member CNTNAP2 (CASPR2) [37]. According to TCGA database (portal.gdc.cancer.gov) 
[38], 28 different CNTNAP4 mutations were identified in 6.80% (28/412) of UC. CNTNAP4 
mutations were also identified at a high frequency in lung, colorectal cancer, and melanoma 
(68-82%), and at a lower frequency in breast cancer (15%). Mutation at the G727 site, G727V 
has been identified in colorectal cancer [39], however, G727* mutation has not been reported 
so far.  
 Stratification strategies for NAC and surveillance in conjunction with cftDNA analysis 
have been proposed [14, 16]. Use of cftDNA monitoring in the course of checkpoint 
immunotherapy is also possible [40, 41]. A novel concept of an integrated monitoring system, 
such as continuous individualised risk index (CIRI) is based on the advance of cftDNA-based 
technologies [5]. The cost effectiveness of ddPCR should be carefully evaluated, as repeat 
cystoscopies are expensive for health services [42] and tests for several mutations in genes 
such as FGFR3, PI3KCA, and TP53 are already available as molecular diagnostic services 
offered by the National Health Service in the UK. Given that the cfDNA technology has still 
not been implemented widely in the health service, clinical applicability of ddPCR-based 
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Monitoring of urothelial cancer disease status after treatment by digital droplet PCR 
liquid biopsy assays  




Preparation of plasma, buffy coat, peripheral blood mononucleocytes (PBMCs), and urine 
 
 Nine ml of blood was added to a S-Monovette EDTA tube (Sarstedt, Numbrecht, 
Germany) and mixed by inverting several times. The samples were centrifuged at 1600g for 
10 minutes at 4°C in a swing out head centrifuge. The plasma was placed into cryotubes 
(Alpha Labs, Eastleigh, UK) in 1-ml aliquots and centrifuged for a further 10 minutes at 
13200 rpm at room temperature. The resulting supernatant was stored in cryotubes at -80°C. 
The buffy coat was collected by aspiration after plasma was removed, and stored in 1-ml 
cryotubes at -80°C. PBMCs were processed from 6 ml of blood in an EDTA vacutainer (BD, 
Workingham, UK). Five ml of HISTOPAQUE-1077 (Sigma-Aldrich, Gillingham, UK) was 
added to a 15-ml tube and layered with 5 ml of blood. Four layers were visible after 
centrifugation at 600g for 20 minutes. The plasma (top layer) was discarded. PBMC (the 
second layer above a clear bottom layer) was transferred into a clean 15-ml tube. Ten ml of 
ice-cold PBS was added, and the sample was centrifuged at 500g for 10 minutes at 4°C. The 
pellet was resuspended in 1 ml of ice-cold PBS and transferred to a 1.5-ml Eppendorf tube and 
centrifuged for 5 minutes at 500g at 4°C. The supernatant was discarded and the PBMCs 
(pellet) were stored at -80°C. Voided urine collected from patients (10 ml) was added with 
200 µl of 0.5 M EDTA, pH 8 (Thermo Fisher Scientific, UK #15575020) to achieve a final 




DNA Extraction  
 
 DNA was extracted using the QIAamp FFPE Tissue Kit (Qiagen, Manchester, UK) and 
eluted in 70-100 µl of buffer ATE or molecular-grade water. DNA was extracted from PBMCs 
using the QIAamp Blood Mini Kit (Qiagen) and eluted in 100 µl buffer AE. Plasma and urine 
DNAs were extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen) and eluted in 
40 µl buffer AVE. DNA was stored at -20°C. DNA was quantified using Qubit High 
Sensitivity DNA or Broad Range DNA Kits (ThermoFisher Scientific, Loughborough, UK). 
For WES, genomic DNA samples from patient tumour and matched PBMCs were assessed by 
Agilent Tapestation (Agilent, Santa Clara, CA USA) and Qubit 3.0 (ThermoFisher, 
Loughborough, UK). 
 
SNaPshot assay  
 
 Ten ng of DNA was mixed with 1X PCR buffer (Promega, Southampton, UK), 1.5 
mM MgCl2, 0.17 mM dNTPs, 0.7 µM of each primer, 5% glycerol, 1 unit GoTaq DNA 
polymerase (Promega), in a total volume of 15 µl. The thermal cycler conditions were an 
initial denaturation at 95°C for 5 minutes, followed by 45 cycles of 95°C for 45 seconds, 60°C 
for 45 seconds and 72°C for 45 seconds and a final extension for 10 minutes at 72°C. PCR 
products were treated with 3 units of shrimp alkaline phosphatase and 2 units of exonuclease I 
to remove excess dNTPs and primers. SNaPshot assay was carried out using an Applied 
Biosystems SNaPshot Multiplex Kit (ThermoFisher Scientific). The reaction consisted of 2.5 
µl of SNaPshot Ready Multiplex Mix, 1X BigDye sequencing buffer, 1 µl of probe mix and 1 
µl of PCR product in a total volume 9 µl. The extension reactions were performed in a thermal 
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cycler and consisted of 35 cycles of denaturation at 95°C for 10 seconds and annealing at 
58.5°C for 40 seconds. Products were treated with 1 unit of shrimp alkaline phosphatase and 
diluted 1 in 10. The diluted product (1 µl) was mixed with 9.8 µl HiDi formamide 
(ThermoFisher Scientific) and 0.2 µl 120 LIZ-standard (ThermoFisher Scientific). Analysis 




 PCR was used to amplify regions covering exons 5 and exon 8 [1] and exon 7 [2] of 
TP53 with following cycle: 95°C for 5 minutes; 30 cycles of 93°C for 45 seconds, 57°C (exon 
5), 59°C (exon 7) or 55°C (exon 8) for 45 seconds and 72°C for 1 minute; and 72°C for 5 
minutes. PCR products were purified using QIAquick PCR purification kit (Qiagen, 
Manchester, UK).  
 
PIK3CA E542K and TP53 Y163C ddPCR assays  
 
 The assays used were; PIK3CA E542K, #dHsaCP2000073 FAM Mutant, 
#dHsaCP2000074 HEX Wild Type, and TP53 Y163C, #dHsaCP2000099 FAM Mut, 
#dHsaCP2000100 HEX WT (BioRad, Watford, UK). Assays were performed in reactions 
containing 2 µl of DNA, 12.5 µl SuperMix no dUTP (BioRad), 1.25 µl FAM Primers and 1.25 
µl of HEX Primers and 1µl of Alu1 (NEB, Hitchin, UK) or Tru1 (ThermoFisher Scientific). 
PCR was performed as follows; 95°C for 10 minutes then 40 cycles of 94°C for 30 seconds 
and 55°C for 1min followed by 98°C for 10 minutes, and a final hold at 4°C. The LOD of 
PIK3CA E542K and TP53 Y163C ddPCR assays is 0.1% (PrimePCR ddPCR Mutation Assay 
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Validation Data, BioRad). The criteria for positive calling was >3 droplets, as suggested by 
BioRad, or >1 droplet if the result was replicable in more than 3 independent experiments.  
 
Design of new ddPCR assays 
 
 The ddPCR assays (PCR primers and probes) for TERT -124 and CNTNAP4 G727* 
were designed using Primer 3Plus [3] with the Human GRCh37 as a reference sequence. The 
specificity of the sequences was evaluated by PrimerBlast and an in-silico PCR run 
(genome.ucsc.edu/cgi-bin/hgPcr). 
 
TERT -124 ddPCR assay 
 
 The TERT -124 assay was optimised using a TERT vector DNA. The TERT vector 
DNA construct (a gift from Dr Alan Bilsland and Professor W. Nicol Keith, University of 
Glasgow, UK) was generated from pGL3-hTERT [4] using a QuikChange Lightning Site 
Directed Mutagenesis kit (Agilent) and the primers TERT-124 Forward (5’-
ccccggcccagccccttccgggccctcccag-3’) and TERT-124 Reverse (5’-
ctgggagggcccggaaggggctgggccgggg-3’). The complete 574bp promoter region was 
sequenced. The promoter was excised from a clone found to be positive for the mutation 
using XhoI/HindIII digest and re-inserted in the pGL3 (Promega) plasmid backbone. The 
TERT -124 ddPCR assay was carried out using a forward primer 
GTCCTGCCCCTTCACCTT, reverse primer CAGCGCTGCCTGAAACTC [5, 6], mutant 
probe CAGCCCCTTCCGGGCCCT and wild type probe CAGCCCCCTCCGGGCCCT. The 
PCR was as follows; 95°C for 10 minutes then 50 cycles of 94°C for 30 seconds and 60°C for 




CNTNAP4 G727* ddPCR assay 
 
 The assay was carried out using a forward primer CCTCTGAGTTGGTGGGTAGG, 
reverse primer CACCATTCATTCCGGTCAG, mutant probe 
CTTGTGGATTAGAGTGAAACTGCATTG and wild type probe 
TGTGGATTAGAGGGAAACTGCATT. The assay was optimised using oligo DNA 
synthesised by IDT, Leuven, Belgium, and Human-Random-Control-DNA-5 (HRC-5) 
(Public Health England, Salisbury, UK). The PCR was as follows; 95°C for 10 minutes then 
50 cycles of 94°C for 30 seconds and 61°C for 1min followed by 98°C for 10 minutes and a 




ddPCR analysis of a PIK3CA E542K, TP53 P278T, and FGFR3 K650/652M, in additional 
patients 
 The PIK3CA E545K ddPCR assay also successfully detected mutations in tumour 
DNA samples from Patients 13 and 17, and correctly called Patient 19 negative for the 
mutation (data not shown). No plasma samples were available for these patients for 
monitoring.  
 A TP53 mutation in exon 8 (P278T) was identified in Patient 8, however a ddPCR 
assay was not commercially available. Patient 1 was identified with a FGFR3 K650/652M 
mutation (Table 2). While an in silico designed ddPCR assay was commercially available, we 
were not able to eliminate the false positive signal. Several in-house assays were designed, 




A new TERT -124 ddPCR assay can detect TERT -124 mutations in cases below the 
SNaPshot assay detection limit 
 
Using a new set of probes and previously reported PCR amplification primers [5, 6], a 
new ddPCR assay for TERT promotor -124 mutation was designed and tested. An optimal 
annealing temperature was identified as 60°C with 50 cycles for the PCR (Fig. S1A). An 
optimal ratio of the wildtype to mutant probes of 50:50 was established (Fig. S1B). The primer 
to probe ratio was optimal at 1.8:1 (Fig. S1C). We determined the sensitivity of the assay by 
spiking mutant vector DNA into wild type vector DNA. Plotting the observed fractional 
abundance (FA) of the mutant allele against the expected FA, presented as a solid line (Fig. 
S1D), we have examined the linear relationship between observed and expected mutant FA. 
We observed that the lower points of observed FA were away from, and not in alignment with, 
the linear decline of the expected FA. Based on this, we determined the limit of detection 
(LOD) of this assay as 0.5%.  
 Next, we performed the ddPCR assay using 9 samples in which the SNaPshot assay 
had previously indicated the presence of a TERT -124 mutation. Using the tumour DNA that 
ranged between 1 ng to 20 ng as a template, the production of mutant droplets was clearly 
observed (Fig. S2B and data not shown). The FA of the mutant allele of the 9 tumours ranged 
from 27% to 67% (Fig. S2A).  
 A further 9 patients were identified as negative for the TERT -124 mutation by 
SNaPshot analysis of their tumour DNA (Table 1, Table 2). Using the ddPCR assay, no 
mutant droplets were observed in 5 out of 9 patients (Patients 6, 9, 19, 20 and 21) in 
accordance with SNaPshot (Fig. S2C, D and data not shown). In contrast, 4 out of 9 (Patients 
2, 8, 12 and 13) produced mutant droplets (Fig. S2C and data not shown). The FA of the 
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mutant allele in the tumour of Patent 2 was 7%, and therefore above the LOD of the ddPCR 
assay (Fig. S2E). The FA was below the LOD in the other 3 cases (Patient 8, 12, 13).   
 Taken together, the above results showed that the new TERT -124 ddPCR assay was 
able to detect the presence of the TERT -124 mutation correctly.  
 
The ddPCR assay for CNTNAP4 G727* mutation 
 
WES performed in DNAs extracted from FFPE tumours (n=3) were compared with the 
results from the corresponding patient's PBMCs for the presence of germ-line mutations (Fig 
S3A). From a total of 19674 (Patient 6) and 39776 (Patient 4) tumour-specific mutations 
identified, systematic filtering of small nucleotide polymorphisms (SNPs) resulted in 54 and 
249 mutations, respectively, that could be used in the development of ddPCR assays to track 
the presence of cftDNA (Fig. S3B, C). In consideration of regional variations in mutations 
within the same tumour samples (Fig. 4A), we further filtered the mutations to include those 
that were in at least 10% of the total number of reads and with a depth of >50. 
 A ddPCR assay was designed for CNTNAP4 G727* mutation (Fig. S4). The optimal 
annealing temperature was established as 61°C with 50 cycles (Fig. S4A). The optimal wild 
type and mutant probe ratio was identified as 50:50 (Fig. S4B). The primer to probe ratio was 
optimal at 2:1 (Fig. S4C).  The new assay was tested using tumour DNA from Patient 5 and 
HRC-5 DNA as a negative control. The LOD of the assay was determined as 1% FA of the 
mutant allele, as the observed values were not aligning with the expected at mutant FA lower 
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Fig. S1: Optimisation of the new TERT -124 ddPCR assay. (A) Identification of optimal 
annealing temperature across a temperature gradient from 50°C to 70°C. (B) Establishment of 
wildtype (WT) probe to mutant (Mut) probe ratio to achieve the best specificity for each WT and 
Mut template DNA. (C) Identification of the optimal primer to probe ratio. (D) Observed and 
expected fractional abundance of the mutant allele was used to determine the level of detection 
(LOD). 
Fig. S2: Detection of the TERT promoter -124 mutation by a new ddPCR assay. We have used 
a new ddPCR assay to investigate the TERT -124 mutation status in tumour DNAs that had been 
previously identified by SNaPshot as positive (A, B) or negative (C-D). Fractional abundance of 
the mutant allele (A, C). The representative plots of TERT -124 -positive (Patient 11), and -
negative (Patient 9) cases are shown (B, D). Tumour DNA from Patient 2 was identified as 
positive by the ddPCR assay, while previously identified as negative by SNaPshot (E).
Fig. S3: Whole exome sequencing (WES) of tumours from three patients. (A) Summary 
details of three patient’s tumour samples that have been subjected to WES. (B) The approach used 
to filter the sequencing results to identify candidate mutations for ddPCR assays. (C) Numbers of 
mutations identified in tumours from three patients. Three proximate areas of the tumour from 
Patient 5 (5-1, 5-2, 5-3) were also compared. 






4 Male 67 pT2 G3 FFPE PBMC
5 Male 81 pT2 G3 FFPE PBMC
6 Male 67 pT2 G3 FFPE PBMC
Step Filter
1 Remove Intergenic and IG mutations
2 Remove RNA Mutations
3 Remove synonymous mutations
4 Remove splice variants
5 Remove downstream mutations
6 Remove intron mutations
7 Remove 5” and 3” UTR mutations
8 Remove upstream mutations
9 Remove transcription factor binding site mutations
10 Remove low effect mutations
11 Remove mutations lacking complete data
12 Remove mutations not identified in the COSMIC database
13 Remove all mutations with a read depth <50
Filter Stage Patient-Sample
4 5-1 5-2 5-3 6
Raw Tumour 193252 113215 97472 114171 103848
Tumour-Germ line 39776 19883 19858 21785 19674
SNP’s 31382 18254 18958 20840 18593
Insertions 7007 1134 518 509 695
Deletions 1386 495 382 436 386
Variant rate (/Mb) 12.9 6.4 6.4 7.0 6.4




Fig. S4: Characteristics of the developed CNTNAP4 G727* ddPCR assay. (A) Identification 
of optimal annealing temperature using a temperature gradient. (B) Establishment of WT probe to 
Mut probe ratio to achieve the best specificity for each WT and Mut template DNA. (C)
Identification of the optimal primer to probe ratio. (D) Observed and expected fractional 
abundance of the mutant allele was used to determine the LOD.
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Highlights: 
• Digital Droplet PCR assays of tumour-specific mutations can be used to monitor cell 
free tumour DNA levels in plasma and urine in urothelial cancer patients. 
• Seventy percent of the patients in our study harboured mutations that were assayable 
by ddPCR. 
• Commercially available ddPCR assays for PIK3CA E542K and TP53 Y163C can be 
used to assess disease status.  
• A new ddPCR assay for TERT promotor (-124) enables detection at a lower fractional 
abundance than SNaPshot.  
• A ddPCR assay was developed to detect a novel mutation, CNTNAP4 G727*. 
 
